Evotec
Martin Arthuis is a distinguished scientist with extensive experience in the field of organic chemistry and pharmaceutical research. Currently serving as a Group Leader and Senior Research Scientist at Evotec since October 2014, Martin specializes in the conception and synthesis of new anti-infective agents. Prior to this role, a Postdoctoral Research Associate position was held at the University of Zurich from March 2011 to September 2014, focusing on the total synthesis of natural products. Martin also worked as a Postdoctoral Research Associate at CNRS ICSN from November 2009 to November 2010, and completed a PhD as a candidate at Institut Curie, where research involved palladium-catalyzed domino reactions for the synthesis of constrained analogues of Combretastatin A4. Martin holds a combined Ph.D. and Pharm D degree in Organic Chemistry and Pharmacy from Paris Descartes, obtained in 2009.
This person is not in the org chart
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.